AvenCell Therapeutics, Inc., a leading clinical-stage cell therapy company focused on advancing both switchable and allogeneic CAR-T cell therapies, today announced that it has dosed the first patient ...
Concurrent statin therapy was associated with significantly improved survival outcomes and reduced neurotoxicity in patients ...
Please provide your email address to receive an email when new articles are posted on . CD19 CAR T-cell therapy controlled lupus, idiopathic inflammatory myositis and systemic sclerosis in 15 patients ...
Credit: Getty Images. KYV-101 is a novel, fully human anti-CD19 chimeric antigen receptor T-cell therapy. The Food and Drug Administration (FDA) has granted Fast Track designation to KYV-101 for the ...
Add Yahoo as a preferred source to see more of our stories on Google. LBCL continues to present major clinical challenges despite improvements with chemoimmunotherapy. Credit: SVStocker via ...
The study will assess the number and severity of dose-limiting toxicities and adverse events. A new study will evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in ...
A next-generation, anti-CD19 enhanced CAR T-cell therapy that secretes interleukin-18 achieved a response in 81% of lymphoma patients who failed previous CAR T-cell therapy. Duration of response was 9 ...
Researchers from Kyverna Therapeutics Inc. presented preclinical data for KYV-101, a first-in-class, fully human autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy being developed for ...
Andrew Zelenetz, MD, PhD, addresses the potential for CD19 antigen loss, the lack of robust data, and the influence of newer, highly efficacious combination therapies on the sequencing decisions in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results